Partnership objective
Transfer of scientific knowledge and technology to improve access to treatment for Parkinson’s Disease in Brazil.

Description of partnership activities and how they address needs and challenges
This private-public partnership (PPP) was set up between Boehringer Ingelheim and the Ministry of Health of Brazil in order to transfer the technology used in the treatment of Parkinson’s disease, pramipexole immediate-release. This is with a view to reducing the cost of treatment and speeding up drug access for patients. The collaboration agreement also aims to put the government in the position to reduce the country’s dependence on imported drugs.